A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia

Francis Giles*, Srdan Verstovsek, Stefan Faderl, Norbert Vey, Judy Karp, Gail Roboz, Khuda Dan Khan, Maureen Cooper, Syed Fazl Ali Bilgrami, Augustin Ferrant, Simon Daenen, Verena Karsten, Ann Cahill, Maher Albitar, Hagop Kantarjian, Susan O'Brien, Eric Feldman

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

24 Scopus citations

Fingerprint

Dive into the research topics of 'A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences